Therapeutic potential of non-competitive, subtype-selective metabotropic glutamate receptor ligands

Bibliography

• BOCKAERT J, PIN JP: Molecular tinkering of G protein-coupled receptors: an evolutionary success. EMBO J. (1999) 18(7):1723–1729.
   PubMed Web of Science ®Google Scholar
• PARMENTIER ML, PREZEAU L, BOCKAERT J, PIN JP : A model for the functioning of family 3 GPCRs. Trends Pharmacol Set. (2002) 23(6):268–274.
   PubMed Web of Science ®Google Scholar
• ••An excellent introduction to the uniqueallosteric properties of family 3 GPCRs.
   Google Scholar
• SCHOEPP DD: Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J. Pharmacol Exp. The]: (2001) 299(1):12–20.
   PubMed Web of Science ®Google Scholar
• SCHOEPP DD, JANE DE, MONN JA: Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology(1999) 38(10):1431–1476.
   PubMed Web of Science ®Google Scholar
• •A fairly complete picture of the pharmacology of mGlu receptor competitive ligands.
   Google Scholar
• PAGANO A, RUEGG D, LITSCHIG S et al.: The non-competitive antagonists 2-methy1-6-(phenylethynyOpyridine and 7-hydroxyiminocyclopropan [b] chromen-la- carboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group I metabotropic glutamate receptors. j. Biol. Chem. (2000) 275(43):33750–33758.
   PubMedGoogle Scholar
• LITSCHIG S, GASPARINI F, RUEEGG D et al.: CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signalling without affecting glutamate binding. Ma Pharmacol (1999) 55(3):453–461.
   PubMedGoogle Scholar
• ••The first molecular characterisation of an allostric binding site in the seven TM domain of mGlu receptors.
   Google Scholar
• GASPARINI F, KUHN R, PIN JP: Allosteric modulators of group I metabotropic glutamate receptors: novel subtype-selective ligands and therapeutic perspectives. Current Opin. Pharmacol (2002) 2:43–49.
   PubMed Web of Science ®Google Scholar
• DE VRY J, HORVATH E, SCHREIBER R: Neuroprotective and behavioural effects of the selective metabotropic glutamate mGlu(1) receptor antagonist BAY 36-7620. Eur. Pharmacol (2001) 428(2):203–214.
   PubMedGoogle Scholar
• CARROLL FY, STOLLE A, BEART PM et al.: BAY36-7620: a potent non-competitive mGlul receptor antagonist with inverse agonist activity. Ma Pharmacol (2001) 59(5):965–973.
   PubMedGoogle Scholar
• SOUDIJN W, VAN WIJNGAARDEN I, IJZERMAN AP: Allosteric modulation of G protein-coupled receptors. Expert Opin. Patents (2001) 11(12):1889–1904.
   Google Scholar
• IJZERMAN A, KOUROUNAKIS A, VAN DER KLEIN P: Allosteric modulation of G protein-coupled receptors. Farmaco. (2001) 56(1-2):67–70.
   PubMedGoogle Scholar
• CHRISTOPOULOS A: Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nature Review Drug Discovery (2002) 1:198–210.
   PubMed Web of Science ®Google Scholar
• ••A very good review on the properties ofGPCR allosteric modulators.
   Google Scholar
• CHRISTOPOULOS A, KENAKIN T: G protein-coupled receptor allosterism and complexing. Pharmacol Rev. (2002) 54(2):323–374.
   PubMed Web of Science ®Google Scholar
• GASPARINI F, FLOERSHEIM P, FLOR PJ et al.: Discovery and characterization of non-competitive antagonists of group I metabotropic glutamate receptors. Farmaco. (2001) 56(1-2):95–99.
   PubMedGoogle Scholar
• KNOFLACH F, MUTEL V, JOLIDON S et al.: Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action and binding site. Proc. Natl. Acad. Sci. USA. (2001) 98(23):13402–13407.
   PubMedGoogle Scholar
• •An extensive characterisation of the first positive allosteric modulators of mGlul receptors.
   Google Scholar
• GASPARINI F, LINGENHOHL K, STOEHR N et al.: 2-Methy1-6-(phenylethynyl) -pyridine (MPEP), a potent, selective and systemically active mG1u5 receptor antagonist. Neurophannacology (1999) 38(10):1493–1503.
   PubMed Web of Science ®Google Scholar
• VARNEY MA, COSFORD ND, JACHEC C et al: SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor Type 5. j. Pharmacol Exp. Ther. (1999) 290(1):170–181.
   PubMedGoogle Scholar
• WALKER K, BOWES M, PANESAR M et al.: Metabotropic glutamate receptor subtype 5 (mG1u5) and nociceptive function. I. Selective blockade of mG1u5 receptors in models of acute, persistent and chronic pain. Neurophannacology (2001) 40(1):1–9.
   Google Scholar
• WALKER K, REEVE A, BOWES M et al.: mG1u5 receptors and nociceptive function II. mG1u5 receptors functionally expressed on peripheral sensory neurons mediate inflammatory hyperalgesia. Neurophannacology(2001) 40(1):10–19.
   Google Scholar
• BHAVE G, KARIM F, CARLTON SM, GEREAU RW 4th: Peripheral group I metabotropic glutamate receptors modulate nociception in mice. Nat. Neurosci. (2001) 4(4):417–423.
   PubMedGoogle Scholar
• KARIM F, BHAVE G, GEREAU RW 4th: Metabotropic glutamate receptors on peripheral sensory neuron terminals as targets for the development of novel analgesics. Ma Psychiatry(2001) 6(6):615–617.
   Google Scholar
• SPOOREN WP, VASSOUT A, NEIJT HC et al.: Anxiolync-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyflpyridine in rodents. J. Pharmacol Exp. Titer. (2000) 295(3):1267–1275.
   PubMed Web of Science ®Google Scholar
• SCHULZ B, FENDT M, GASPARINI F, LINGENHOHL K, KUHN R, KOCH M: The metabotropic glutamate receptor antagonist 2-methy1-6-(phenylethynyfl-pyridine (MPEP) blocks fear conditioning in rats. Neurophannacology(2001) 41(1):1–7.
   PubMedGoogle Scholar
• CHIAMULERA C, EPPING- JORDAN MP, ZOCCHI A et al.: Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat. Neurosci. (2001) 4(9):873–874.
   PubMedGoogle Scholar
• GATTI S, KNOFLACH F, KEW JNC et al.: 8-phenyethyny1-1,3Dihydrobenzo [b] [1,4] diazepin-2one derivatives are potent non-competitive metabotropic glutamate receptor 2/3 antagonists. Soc. Neurosci. Abst. (2001) 27: 705.10
   Google Scholar
• BALLARD TM, KEW JNC, RICHARDS JG et al.: Pharmacological and genetic evidence for an important modulatory role of mG1u2 receptors on cognitive function. Soc. Neurosci. Abst. (2001) 27: 705.11
   Google Scholar